Background: Eosinophilic bronchitis without asthma causes chronic coughs without the physiologic features of asthma. The aim of this study was to review the clinical features, pathogenesis, diagnosis, treatment and prognosis of this condition. Methods: The current literature was reviewed using Pubmed for all studies published in the English language using the search term ‘eosinophilic bronchitis’. Results: Eosinophilic bronchitis presents as normal spirometry, without evidence of airway hyperresponsiveness, and normal peak expiratory flow variability. When compared with asthma, mast cell recruitment to the superficial airways and mast cell activation appear to be a feature of eosinophilic bronchitis. In contrast, mast cell infiltration in the smooth muscle is significantly higher in asthma patients than in either eosinophilic bronchitis patients or healthy control subjects. In this condition, the absence of high IL-13 expression can contribute to the normal airway reactivity. The cough usually responds well to inhaled corticosteroids but dose and duration of treatment remain unclear. The condition can be transient, episodic or persistent unless treated, and occasionally, patients may require long-term treatment with oral corticosteroids. Conclusions: The condition is an important cause of chronic coughs which are corticosteroid responsive. The study of eosinophilic bronchitis suggests that eosinophil-dependent mechanisms are generally not important in the pathogenesis of asthma.

Keywords:
Eosinophil leukocytes, Bronchitis, Asthma, Eosinophilic inflammation
1.
Gonlugur U, Efeoglu T: Vascular adhesion and transendothelial migration of eosinophil leukocytes. Cell Tissue Res 2004;318:473–482.
2.
Gonlugur U, Gonlugur TE: Non-allergic eosinophilic inflammation. Immunol Invest 2006;35:29–45.
3.
Gibson PG, Dolovich J, Denburg J, Ramsdale EH, Hargreave FE: Chronic cough: eosinophilic bronchitis without asthma. Lancet 1989;i:1346–1348.
4.
Brightling CE, Ward R, Goh KL, Wardlaw AJ, Pavord ID: Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999;160:406–410.
5.
Berry MA, Hargadon B, McKenna S, Shaw D, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy 2005;35:598–601.
6.
Brightling CE, Pavord ID: Eosinophilic bronchitis. What is it and why is it important? Clin Exp Allergy 2000;30:4–6.
7.
Brightling CE, Ward R, Wardlaw AJ, Pavord ID: Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J 2000;15:682–686.
8.
Park SW, Lee YM, Jang AS, Lee JH, Hwangbo Y, Kim DJ, Park CS: Development of chronic airway obstruction in patients with eosinophilic bronchitis. A prospective follow-up study. Chest 2004;125:1998–2004.
9.
Fujimura M, Ogawa H, Yasui M, Matsuda T: Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy 2000;30:41–47.
10.
Gibson PG, Zlatic K, Scott J, Sewell W, Woolley K, Saltos N: Chronic cough resembles asthma with IL-5 and granulocyte macrophage colony stimulating factor gene expression in bronchoalveolar cells. J Allergy Clin Immunol 1998;101:320–326.
11.
Birring SS, Berry M, Brightling CE, Pavord ID: Eosinophilic bronchitis: clinical features, management and pathogenesis. Am J Respir Med 2003;2:169–173.
12.
Bhowmik A, Seemungal TA, Sapsford RJ, Devalia JL, Wedzicha JA: Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998;53:953–956.
13.
Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE: Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161:475–478.
14.
Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, Bianchi A, Michetti G: Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 2000;162:1172–1174.
15.
Krakowiak AM, Dudek W, Ruta U, Palczynski C: Occupational eosinophilic bronchitis without asthma due to chloramine exposure. Occup Med 2005;55:396–398.
16.
Ogawa H, Fujimura M, Heki U, Kitagawa M, Matsuda T: Eosinophilic bronchitis presenting with only severe dry cough due to bucillamine. Respir Med 1995;89:219–221.
17.
Di Stefano F, Di Giampaolo L, Verna N, Di Gioacchino M: Occupational eosinophilic bronchitis in a foundry worker exposed to isocyanate and a baker exposed to flour. Thorax 2007;62:368–370.
18.
Yacoub MR, Malo JL, Labrecque M, Cartier A, Lemiere C: Occupational eosinophilic bronchitis. Allergy 2005;60:1542–1544.
19.
Gibson PG, Fujimura M, Niimi A: Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002;57:178–182.
20.
Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID: Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003;58:528–532.
21.
Park SW, Jangm HK, An MH, Min JW, Jang AS, Lee JH, Park CS: Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis. Comparison with asthma. Chest 2005;128:1921–1927.
22.
Brightling CE, Ward R, Woltmann G, Bradding P, Sheller JR, Dworski R, Pavord ID: Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000;162:878–882.
23.
Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID: Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699–1705.
24.
Woodman L, Sutcliffe A, Kaur D, Berry M, Bradding P, Pavord ID, Brightling CE: Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects. Chest 2006;130:371–378.
25.
Schulman ES, MacGlashan DW, Schleimer RP, Peters SP, Kagey-Sobotka A, Newball HH, Lichtenstein LM: Purified human basophils and mast cells: current concepts of mediator release. Eur J Respir Dis 1983;128:53–61.
26.
Brightling CE: Chronic cough due to nonasthmatic eosinophilic bronchitis. ACCP evidence-based clinical practice guidelines. Chest 2006;129:116S–121S.
27.
Berry MA, Parker D, Neale N, Woodman L, Morgan A, Monk P, Bradding P, Wardlaw AJ, Pavord ID, Brightling CE: Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004;114:1106–1109.
28.
Thomson NC, Chaudhuri R: Why is eosinophilic bronchitis not asthma? Am J Respir Crit Care Med 2004;170:4–5.
29.
Kanazawa H, Nomura S, Yoshikawa J: Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004;169:1125–1130.
30.
Siddiqui S, Sutcliffe A, Shikotra A, Woodman L, Doe C, McKenna S, Wardlaw A, Bradding P, Pavord I, Brightling C: Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol 2007;120:813–819.
31.
Hancox RJ, Leigh R, Kelly MM, Hargreave FE: Eosinophilic bronchitis. Lancet 2001;358:1104.
32.
Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID: Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. Eur Respir J 1999;14:1228–1230.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.